- Record: found
- Abstract: not found
- Article: not found
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam ,
Randy F. Sweis ,
F. Stephen Hodi ,
Wells A. Messersmith ,
Robert H.I. Andtbacka ,
Matthew Ingham ,
Nancy Lewis ,
Xinhui Chen ,
Marc Pelletier ,
Xueying Chen ,
Jincheng Wu ,
Sarah M. McWhirter ,
Thomas Müller ,
Nitya Nair ,
Jason J. Luke
October 29 2021
Read this article at
ScienceOpenPublisherPubMed
- open (via free pdf)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via OAI-PMH title and first author match)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815
(ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of
IFN genes (STING) pathway, in patients with advanced/metastatic cancers.